Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
SAN DIEGO, June 20, 2025 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx received European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) developed with ENHANZE®, Halozyme's proprietary recombinant human hyaluronidase enzyme (rHuPH20), for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins.
VYVGART is the first and only targeted IgG Fc-antibody fragment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and the first novel mechanism of action for CIDP treatment in more than 30 years.
'We are pleased to announce the European Commission approval of the subcutaneous injection of VYVGART, which is co-formulated with our ENHANZE drug delivery technology for use in CIDP patients. This marks another milestone in our partnership with argenx and the expansion of access to Europe is another catalyst supporting our growth,' said Dr. Helen Torley, president and chief executive officer of Halozyme.
The EC decision is based on positive results from the ADHERE clinical trial, the largest study of CIDP patients to date. For more information on the study and its findings, please view argenx's press release issued on June 20, 2025.
The approval by the EC is valid in all 27 European Union (EU) Member States, as well as Iceland, Norway and Liechtenstein.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.
Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility.
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Safe Harbor Statement
In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients, including a potential reduction in administration time and broadening the treatment options for the indication referred to in this press release. Forward-looking statements may also include statements regarding potential growth catalysts and opportunities driven by the product development and commercialization efforts of Halozyme's ENHANZE® partners. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words 'expect,' 'believe,' 'enable,' 'may,' 'will,' 'could,' 'intends,' 'estimate,' 'anticipate,' 'plan,' 'predict,' 'probable,' 'potential,' 'possible,' 'should,' 'continue,' and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including uncertainties concerning unexpected results or delays in the timing of the Halozyme's expected growth catalysts or in the launch or commercialization of our partner's product for the indication referred to in this press release, unexpected adverse events or patient experiences or outcomes from being treated with the ENHANZE® co-formulated treatment referred to in this press release, and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Contacts:
Tram BuiVP, Investor Relations and Corporate Communications609-333-7668tbui@halozyme.com
Sydney CharltonTeneo 917-972-8407 sydney.charlton@teneo.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
5 hours ago
- Malaysian Reserve
Caris Life Sciences Announces New Study Demonstrating the Power and Clinical Utility of its Caris Assure® Blood-Based Assay for Multi-Cancer Early Detection, Minimal Residual Disease and Therapy Selec
Scientific Reports study validates the first multifunctional, AI-enabled blood-based assay to offer diagnostic, prognostic and predictive utility in a single assay. IRVING, Texas, July 8, 2025 /PRNewswire/ — Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, announced a landmark study published in Scientific Reports, a Nature journal, demonstrating the accuracy and clinical utility of the Caris Assure® blood-based biopsy assay across the cancer continuum. The Caris Assure® platform is a breakthrough single assay that combines comprehensive, highly sophisticated molecular profiling of all 23,000+ genes across DNA and RNA in plasma, setting a new blood-based testing standard and revolutionizing management of the cancer care journey. Additionally, Caris sequences DNA in the 'buffy coat,' the layer of centrifuged blood between the red blood cells and plasma, which contains white blood cells and platelets. Caris Assure combines Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) with advanced machine learning on a single platform. Caris Assure® is currently used for therapy selection and is capable of enabling accurate early detection and highly sensitive disease monitoring. 'We designed Caris Assure® to be more than a liquid biopsy test. This assay takes advantage of advanced sequencing and computing technology to capture genetic information available from the whole exome and whole transcriptome from the tumor material circulating in the blood and DNA from the patient's white blood cells,' said David Spetzler, MS, PhD, MBA, President of Caris. 'This enables us to provide a very comprehensive individualized picture of a patient's specific disease state. This is the first time so much molecular information has been available from a single blood test, allowing for increased accuracy and additional insights to inform physicians in helping to make cancer care decisions.' The Caris Assure® liquid biopsy platform, powered by the Assure Blood-based Cancer Detection AI (ABCDai), was trained on over 376,000 whole exome and whole transcriptome tissue profiles and over 7,000 matched blood and tissue samples. In addition to therapy selection, the study validates the performance of Caris Assure® in: Multi-Cancer Early Detection (MCED): Achieved sensitivities of 83.1% to 95.7% across cancer stages I–IV at 99.6% specificity. Diagnostic Pathway Predictor: Accurately identified the diagnostic pathway for MCED-positive cancers using the ABCDai-GPS model. MRD and Recurrence Monitoring: Demonstrated significant predictive power for recurrence, with hazard ratios of 33.4 (p < 0.005) for MRD and 4.39 (p = 0.008) for therapeutic monitoring. Caris Assure® does not require a prior tissue biopsy. Instead, its AI model identifies tumor-derived signals based on patterns learned from hundreds of thousands of tumors. This enables a tissue-agnostic, highly sensitive approach to cancer detection and monitoring. While Caris Assure® is currently commercially available for therapy selection in advanced cancers, this study lays the groundwork for expanding into early detection, MRD and therapeutic monitoring. Caris is actively pursuing reimbursement and regulatory pathways to bring these applications to market. 'This is more than a validation study; it is a blueprint for the future of cancer diagnostics,' added Spetzler. 'Our goal is to create a seamless ecosystem where patients and clinicians can rely on one platform throughout the entire cancer journey.' About Caris Life Sciences Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development. Caris was founded with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets. The Scientific Report study is available on Forward Looking Statements:This press release contains forward-looking statements, within the meaning of the federal securities laws, about Caris Life Sciences and its business. Statements about the performance and accuracy of Caris Assure discussed in this press release are based on testing and analysis to date, as reflected in the publication discussed, and future results and performance may differ materially from these findings. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases forward-looking statements can be identified by words such as 'may,' 'will,' 'should,' 'would,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'potential,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or similar expressions. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision oncology industry; future financial performance, results of operations or other operational results or metrics; development, validation and timing of future solutions; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; our compliance with laws and regulations; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' and elsewhere in the prospectus for our initial public offering filed with the Securities and Exchange Commission on June 20, 2025, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. Caris Life Sciences Media: Corporate CommunicationsCorpComm@ Investor Relations:Narendra ChokshiSenior Vice President, Corporate Developmentnchokshi@
The Sun
12 hours ago
- The Sun
TUMI Introduces Vibrant Urban-Inspired Fall 2025 Collection
HONG KONG SAR - Media OutReach Newswire - 8 July 2025 - TUMI, the leading international travel, lifestyle and accessories brand, sets the stage for Fall 2025 with exciting new arrivals inspired by the city that never sleeps: New York. This season's collections celebrate the brand's 50-year legacy of innovation and enduring performance. Fall 2025 celebrates the movers, makers and creative spirits that drive the heartbeat of the concrete jungle with creations as multifaceted and resilient as the city itself. Fall 2025 features prints that pay homage to iconic wild postings scattered throughout the city streets. Select pieces from Alpha, Alpha Bravo and Voyageur collections are imagined in Poster Print featuring a torn poster graphic that alludes to the history underpinning all the innovations to come. Alpha Bravo, known for high-performance 'go-anywhere' silhouettes, finds a fresh feel with new core colorway: Navy Coated Canvas, an elevated alternative to classic black. Fall 2025 includes seasonal hues Pavement and Electric Blue, inspired by the metropolis's architecture, as well as new commuter-ready styles— Surveillance Flap Backpack and Roadstead Messenger. This season, men's styles receive an exciting refresh as the premium, automotive-inspired Arrivé collection introduces details like Carbon Fiber accents and quiet, magnetic zipper garages. The relaunch spotlights the Arrivé Large Backpack, refined with modern accents and considered upgrades that elevate function and finish in this most sophisticated silhouette. Crafted with the same precision and polish, Arrivé Hannover Slim Brief is the sleek, minimalist complement for streamlined business travel. Under Fall 2025, the Harrison collection is diversified with styles like Griffen Flap Backpack. Harrison also ushers in Burnished Wine Ombre, a gradient technique that gives its whole-grain leather a distinctive, textured appearance. Inspired by bold graffiti art, TUMI's bestselling Just In Case® styles feature a dripped spray paint design. The signature tote also comes in three new diverse sizes. Folding completely flat, Just In Case® is perfect in every traveler's lineup. This season also introduces colorways across core Voyageur styles—including Celina Backpack—with Mink, TUMI Red and Wine offering elevated versatility for life on the move. Designed with sophistication in mind, brand new Olas and Agent collections expand TUMI's offering for the modern woman. Olas embraces minimalism with clean lines and soft structure in essential silhouettes like the Small and Medium Shoulder Bag. Agent, crafted in lightweight leather and finished with refined hardware, offers a seamless blend of fashion and function, ensuring every detail is thoughtfully considered. The iconic 19 Degree collection returns with seasonal colorways inspired by the atmospheric elegance of autumn in the city's parks. 19 Degree Lite introduces rich, grounded tones of Wine and Pavement—echoing the foliage, stone paths and park surroundings. Moonrock appears in 19 Degree Polycarbonate, extending the palette's quiet sophistication across the broader collection. New to 19 Degree Aluminum comes an unexpectedly opulent 19 Degree Aluminum Bar Set. This luxurious set has everything needed to craft the perfect drink, including exclusive TUMI Cocktail recipe cards. Exquisitely packaged in a premium aluminum case featuring iconic 19 Degree contours, this bar set is the perfect lifestyle piece for TUMI enthusiasts. Rounding out TUMI's 50th anniversary are select travel, lifestyle pieces and accessories featuring the signature TUMI Red Pantone deployed as an accent color and an all-over treatment. Fall 2025 collections are available at TUMI stores worldwide and on Stay tuned for exclusive content featuring Fall 2025 on @TUMITravel social channels.
Malaysian Reserve
14 hours ago
- Malaysian Reserve
Advantech Unveils Next-Generation Edge AI Compute Solutions Powered by Qualcomm Snapdragon X Elite
TAIPEI, July 7, 2025 /PRNewswire/ — Advantech is proud to introduce its latest suite of high-performance edge AI compute solutions powered by the Snapdragon® X Elite platform – the AOM-6731, AIMB-293, and SOM-6820. Built on this groundbreaking platform, these innovative products are engineered to meet the demanding requirements of modern industrial applications by delivering exceptional processing power, integrated AI acceleration with up to 45 TOPS of AI performance, and robust and lightning-fast 5G and Wi-Fi 7 connectivity into an industrial PC. The solutions powered by the Snapdragon X Elite 12-core and Snapdragon® X Plus 10-core with a leading Qualcomm Oryoton™ CPUs, reaching speeds of up to 3.4GHz. This high-performance processing not only ensures enables rapid data handling and seamless multitasking but also outperforms traditional x86 solutions—using 28% less power on average for everyday tasks, including Teams video calls, local video playback, web browsing, and Microsoft 365. Enhancing AI capabilities, these devices are integrated with Qualcomm® Hexagon™ NPU, providing up to 45 TOPS. The solutions, which contain Snapdragon X Elite platforms, are equipped with LPDDR5X memory, offering a 1.3× speed boost—from 6400MT/s to 8533MT/s—while cutting power consumption by 20% compared to standard LPDDR5. In addition, the integration of UFS 3.1 Gear 4 storage dramatically increases data transfer speeds from 1,000Mbps (PCIe Gen3 NVMe) to an impressive 16,000Mbps. For even greater durability and shock resistance, UFS 4.0 storage solutions are available, ensuring optimal performance in harsh industrial environments. For multimedia-intensive applications, the integrated Snapdragon Adreno 5th Generation VPU supports 4K60p full-duplex H.264 video encoding/decoding. Additionally, the Adreno GPU—equipped with OpenCL, OpenGL, and Microsoft DirectX 12 support—ensures superior graphics performance for vision-centric tasks. Advantech's products take connectivity to the next level with integrated Wi-Fi 7 and 5G technologies, delivering ultra-fast, low-latency network performance, ensuring uninterrupted data streaming and real-time communication even in the most demanding industrial settings. With Wi-Fi 7's multi-gigabit speeds and enhanced network reliability combined with the expansive coverage and high-speed capabilities of 5G, these solutions support data-intensive AI applications and robust remote operations. The result is a truly agile and future-ready infrastructure that optimizes real-time processing and connectivity, empowering industries to harness the full potential of edge AI in today's fast-paced digital landscape. The AI module AOM-6731, the Mini-ITX motherboard AIMB-293, and the COM Express Type 6 module SOM-6820—will be available for engineering evaluations starting in March 2025. For further details on these models, please visit Advantech website.
